TCM
APLS

Tygh Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Tygh Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$1.77M Sell
37,542
-75
-0.2% -$2.95K 0.23% 80
2021
Q3 		$1.24M Buy
+37,617
New +$2.11M 0.17% 87

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Tygh Capital Management's APLS Position: Q4 2021 in Review

Tygh Capital Management reduced its Apellis Pharmaceuticals (APLS) stake by 0.2% in Q4 2021, selling an estimated $2.95K and leaving 37,542 shares worth $1.77M. The position accounts for 0.23% of the portfolio, ranked #80.

Tygh Capital Management first reported a position in APLS in Q3 2021 and has held it in 2 quarters since. 187 funds tracked by Wall St. Rank hold APLS as of Q4 2021.

  • Tygh Capital Management held 37,542 shares of Apellis Pharmaceuticals worth $1.77M as of Q4 2021.
  • Tygh Capital Management sold 75 Apellis Pharmaceuticals shares in Q4 2021, an estimated $2.95K.
  • Apellis Pharmaceuticals made up 0.23% of Tygh Capital Management's portfolio in Q4 2021, its #80 holding.
  • Tygh Capital Management first reported a position in Apellis Pharmaceuticals in Q3 2021 and has held it in 2 quarters since.
  • 187 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2021.

Based on Tygh Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.